Vaccination to prevent cervical cancer due to human papillomavirus

Cervical cancer due to human papillomavirus (HPV) is a malignant neoplasm of the uterine cervix triggered by persistent mucosal infection with oncogenic, high-risk genotypes of HPV, most commonly types 16 and 18

Cervical cancer due to human papillomavirus (HPV) is a malignant neoplasm of the uterine cervix triggered by persistent mucosal infection with oncogenic, high-risk genotypes of HPV, most commonly types 16 and 18

Affecting individuals with a cervix, this condition develops through the viral expression of oncoproteins E6 and E7, which disrupt host tumor suppressor pathways, resulting in unchecked cellular proliferation, cervical intraepithelial neoplasia, and eventual invasive carcinoma

Affecting individuals with a cervix, this condition develops through the viral expression of oncoproteins E6 and E7, which disrupt host tumor suppressor pathways, resulting in unchecked cellular proliferation, cervical intraepithelial neoplasia, and eventual invasive carcinoma

Prophylactic vaccination confers active humoral immunity to block primary viral acquisition and subsequent cellular transformation, targeting the female and adolescent populations prior to sexual exposure to prevent cervical precancers and invasive disease

Prophylactic vaccination confers active humoral immunity to block primary viral acquisition and subsequent cellular transformation, targeting the female and adolescent populations prior to sexual exposure to prevent cervical precancers and invasive disease

Prophylactic vaccination confers active humoral immunity to block primary viral acquisition and subsequent cellular transformation, targeting the female and adolescent populations prior to sexual exposure to prevent cervical precancers and invasive disease